Related Experiment Video
Updated: Apr 5, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity
Yee-Lin Voon1, Munirah Ahmad1, Pooi-Fong Wong2
1Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, Kuala Lumpur 50588, Malaysia.
Abstract:
The small-molecule inhibitor of p53-Mdm2 interaction, Nutlin-3, is known to be effective against cancers expressing wild-type (wt) p53. p53 mutations are rare in nasopharyngeal carcinoma (NPC), hence targeting disruption of p53-Mdm2 interaction to reactivate p53 may offer a promising therapeutic strategy for NPC. In the present study, the effects of Nutlin-3 alone or in combination with cisplatin, a standard chemotherapeutic agent, were tested on C666-1 cells, an Epstein-Barr virus (EBV)-positive NPC cell line bearing wt p53. Treatment with Nutlin-3 activated the p53 pathway and sensitized NPC cells to the cytotoxic effects of cisplatin. The combined treatment also markedly suppressed soft agar colony growth formation and increased apoptosis of NPC cells. The effect of Nutlin-3 on NPC cells was inhibited by knockdown of p53, suggesting that its effect was p53-dependent. Extended treatment with increasing concentrations of Nutlin-3 did not result in emergence of p53 mutations in the C666-1 cells. Collectively, the present study revealed supportive evidence of the effectiveness of combining cisplatin and Nutlin-3 as a potential therapy against NPC.
Insights
Nutlin-3, a p53-Mdm2 inhibitor, combined with cisplatin, shows promise for treating nasopharyngeal carcinoma (NPC). This combination reactivates p53, enhances cisplatin
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Nasopharyngeal carcinoma (NPC) rarely harbors p53 mutations, making p53 pathway reactivation a potential therapeutic strategy.
- Nutlin-3, a small-molecule inhibitor, disrupts the p53-Mdm2 interaction, effectively targeting wild-type (wt) p53 cancers.
- Cisplatin is a standard chemotherapeutic agent used in NPC treatment.
Purpose of the Study:
- To investigate the efficacy of Nutlin-3, alone and in combination with cisplatin, against an Epstein-Barr virus (EBV)-positive NPC cell line (C666-1).
- To determine if Nutlin-3 treatment reactivates the p53 pathway and sensitizes NPC cells to cisplatin.
- To assess the p53-dependency of Nutlin-3's effects and evaluate the potential for p53 mutation emergence.
Main Methods:
- Treatment of C666-1 NPC cells with Nutlin-3 and/or cisplatin.
- Assessment of p53 pathway activation and cellular sensitivity to cytotoxic effects.
- Evaluation of soft agar colony formation and apoptosis induction.
- p53 knockdown experiments to confirm p53-dependency.
- Monitoring for p53 mutations during extended Nutlin-3 treatment.
Main Results:
- Nutlin-3 activated the p53 pathway in C666-1 cells.
- Combined Nutlin-3 and cisplatin treatment significantly enhanced NPC cell cytotoxicity.
- The combination therapy suppressed soft agar colony growth and increased apoptosis.
- Nutlin-3's effects were confirmed to be p53-dependent.
- No p53 mutations emerged in NPC cells after extended Nutlin-3 treatment.
Conclusions:
- Nutlin-3 effectively reactivates the p53 pathway in EBV-positive NPC cells.
- Combining Nutlin-3 with cisplatin demonstrates synergistic anti-cancer effects in NPC.
- This combination therapy represents a promising strategy for treating nasopharyngeal carcinoma without inducing p53 mutations.
